Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Prevention of Cardiac Allograft Vasculopathy
NCT01186250Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jul 2010
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pioglitazone in cardiac allograft vasculopathy (CAV), sponsored by Stanford University. Started Jul 2010; status: completed.
02
Drugs
pioglitazone
03
Conditions
cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT01186250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186250.